/ORIC
ORIC Stock - ORIC Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$8.04-0.56%
$0.04 (-0.56%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.25
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.67
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+198.5%upside
Target: $24.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ORIC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.96 – $8.12
TARGET (TP)$24.00
STOP LOSS$7.40
RISK/REWARD1:24.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.32
52W High$14.93
52W Low$3.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,107,000 | $-1,032,000 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-142,895,000 | $-110,780,000 | $-91,767,000 | $-78,871,000 | $-74,186,000 |
| Net Income | $-127,847,000 | $-100,697,000 | $-89,122,000 | $-78,715,000 | $-73,703,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.83 | $-1.96 | $-2.25 | $-2.07 | $-3.36 |
Company Overview
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish0 Neutral/Bearish
Price Targets
$17
Average Target
↑ 108.7% Upside
Now
$8
Low
$17
Average
$25
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 20th 2025 | Evercore ISI | Initiation | Outperform | $25 |
| November 18th 2025 | Wolfe Research | Initiation | Peer Perform | - |
| September 4th 2025 | Guggenheim | Resumed | Buy | $18 |
| July 8th 2025 | Ladenburg Thalmann | Initiation | Buy | $15 |
| October 31st 2024 | Wells Fargo | Initiation | Overweight | $20 |
| September 6th 2024 | Stifel | Initiation | Buy | $20 |
| February 23rd 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| September 22nd 2023 | Wedbush | Initiation | Outperform | $8 |
| March 23rd 2023 | H.C. Wainwright | Upgrade | Buy | $16 |
| March 21st 2023 | Guggenheim | Upgrade | Buy | $15 |
| March 16th 2023 | Oppenheimer | Upgrade | Outperform | $14 |
| July 18th 2022 | Oppenheimer | Resumed | Perform | - |
Earnings History & Surprises
ORICBeat Rate
61%
Last 18 quarters
Avg Surprise
+4.3%
EPS vs Estimate
Beats / Misses
11/6
1 met exactly
Latest EPS
$-0.33
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.49vs$-0.49
Q2 24
+15.9%
$-0.37vs$-0.44
Q3 24
-7.1%
$-0.45vs$-0.42
Q4 24
-2.1%
$-0.49vs$-0.48
Q1 25
+1.9%
$-0.51vs$-0.52
Q2 25
+17.6%
$-0.42vs$-0.51
Q3 25
-2.2%
$-0.47vs$-0.46
Q4 25
+19.5%
$-0.33vs$-0.41
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 17, 2026 | $-0.33 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.41 | $-0.33 | +19.5% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.46 | $-0.47 | -2.2% | ✗ MISS |
Q2 2025 | May 5, 2025 | $-0.51 | $-0.42 | +17.6% | ✓ BEAT |
Q1 2025 | Feb 18, 2025 | $-0.52 | $-0.51 | +1.9% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.48 | $-0.49 | -2.1% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.42 | $-0.45 | -7.1% | ✗ MISS |
Q2 2024 | May 6, 2024 | $-0.44 | $-0.37 | +15.9% | ✓ BEAT |
Q1 2024 | Mar 11, 2024 | $-0.49 | $-0.49 | 0.0% | = MET |
Q4 2023 | Nov 6, 2023 | $-0.46 | $-0.44 | +4.3% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.58 | $-0.50 | +13.8% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.54 | $-0.53 | +1.9% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.56 | $-0.52 | +7.1% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.55 | $-0.63 | -14.5% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.60 | $-0.51 | +15.0% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.57 | $-0.59 | -3.5% | ✗ MISS |
Q1 2022 | Mar 21, 2022 | $-0.61 | $-0.58 | +4.9% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.58 | $-0.47 | +19.0% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.50 | $-0.57 | -14.0% | ✗ MISS |
Latest News
Wells Fargo Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $25
📈 PositiveBenzinga•Dec 8, 2025, 02:50 PM
Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $20 Price Target
📈 PositiveBenzinga•Dec 8, 2025, 02:08 PM
ORIC Pharmaceuticals Enozertinib Shows 35% Objective Response Rate And 100% Disease Control Rate In Human Epidermal Growth Factor Receptor 2 Exon 20 Non-Small Cell Lung Cancer Patients
📈 PositiveBenzinga•Dec 5, 2025, 06:57 AM
ORIC Pharma Announces Two Late-Breaking Oral Presentations Highlighting Data From Phase 1b Trial Of Enozertinib At ESMO Asia Congress 2025
📈 PositiveBenzinga•Dec 3, 2025, 09:03 PM
ORIC Pharmaceuticals Announces Poster Presentation From Phase 1b Study Of Enozertinib At ESMO Asia Congress 2025
➖ NeutralBenzinga•Dec 1, 2025, 01:06 PM
ORIC stock has given up its prior gain. Oric Pharmaceuticals shares were trading higher after Evercore ISI Group initiated coverage on the stock with an Outperform rating and announced a $25 price target.
➖ NeutralBenzinga•Nov 20, 2025, 08:50 PM
Oric Pharmaceuticals shares are trading higher after Evercore ISI Group initiated coverage on the stock with an Outperform rating and announced a $25 price target.
📈 PositiveBenzinga•Nov 20, 2025, 02:15 PM
Evercore ISI Group Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $25
📈 PositiveBenzinga•Nov 20, 2025, 12:31 PM
Wolfe Research Initiates Coverage On ORIC Pharmaceuticals with Peer Perform Rating
➖ NeutralBenzinga•Nov 18, 2025, 05:23 PM
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $20
📈 PositiveBenzinga•Nov 18, 2025, 03:42 PM
Citigroup Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $16
📈 PositiveBenzinga•Nov 17, 2025, 03:14 PM•Also:
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $23
📈 PositiveBenzinga•Nov 14, 2025, 07:02 PM
Oppenheimer Maintains Outperform on ORIC Pharmaceuticals, Raises Price Target to $15
📈 PositiveBenzinga•Nov 14, 2025, 01:13 PM
ORIC Pharmaceuticals Q3 EPS $(0.33) Beats $(0.42) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:45 PM
ORIC Pharmaceuticals Completes Dose Exploration Part Of ORIC-944 Phase 1b Trial
📈 PositiveBenzinga•Nov 13, 2025, 09:25 PM
ORIC Pharmaceuticals Publishes Research Paper On Enozertinib Inhibitor Targeting EGFR Exon 20 Mutations With Exquisite Kinome Selectivity
📈 PositiveBenzinga•Nov 6, 2025, 09:03 PM
ORIC Pharmaceuticals Highlights Preclinical Data At EORTC-NCI-AACR Supporting ORIC-944's Potential For Prostate And Solid Tumor Treatment
📈 PositiveBenzinga•Oct 27, 2025, 12:41 PM
Guggenheim Assumes ORIC Pharmaceuticals at Buy, Announces Price Target of $18
📈 PositiveBenzinga•Sep 4, 2025, 02:12 PM
Frequently Asked Questions about ORIC
What is ORIC's current stock price?
ORIC Pharmaceuticals, Inc. (ORIC) is currently trading at $8.04 per share. The stock has moved -0.56% today.
What is the analyst price target for ORIC?
The average analyst price target for ORIC is $24.00, based on 1 analyst.
What sector is ORIC Pharmaceuticals, Inc. in?
ORIC Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ORIC's market cap?
ORIC Pharmaceuticals, Inc. has a market capitalization of $0.78 billion, making it a small-cap company.
Does ORIC pay dividends?
No, ORIC Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMLX
Amylyx Pharmaceuticals, Inc.
$12.02
Mkt Cap: $1.0B
ATAI
Atai Beckley N.V
$3.96
Mkt Cap: $0.7B
ELVN
Enliven Therapeutics, Inc.
$16.87
Mkt Cap: $1.0B
INBX
Inhibrx Biosciences, Inc.
$86.13
Mkt Cap: $1.3B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
PGEN
Precigen, Inc.
$4.32
Mkt Cap: $1.3B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SNDX
Syndax Pharmaceuticals, Inc.
$20.77
Mkt Cap: $1.8B
TERN
Terns Pharmaceuticals, Inc.
$39.90
Mkt Cap: $3.6B
TRML
Tourmaline Bio, Inc.
$47.98
Mkt Cap: $1.2B
Explore stocks similar to ORIC for comparison